Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Int. J. Mol. Sci. 2013, 14(11), 22933-22966; doi:10.3390/ijms141122933
Review

Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment

,
,
,
 and *
Received: 1 October 2013; in revised form: 30 October 2013 / Accepted: 8 November 2013 / Published: 20 November 2013
(This article belongs to the Special Issue Non-Alcoholic Fatty Liver Disease Research)
View Full-Text   |   Download PDF [328 KB, uploaded 19 June 2014]
Abstract: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide. Several lines of evidence have indicated a pathogenic role of insulin resistance, and a strong association with type 2 diabetes (T2MD) and metabolic syndrome. Importantly, NAFLD appears to enhance the risk for T2MD, as well as worsen glycemic control and cardiovascular disease in diabetic patients. In turn, T2MD may promote NAFLD progression. The opportunity to take into account NAFLD in T2MD prevention and care has stimulated several clinical studies in which antidiabetic drugs, such as metformin, thiazolidinediones, GLP-1 analogues and DPP-4 inhibitors have been evaluated in NAFLD patients. In this review, we provide an overview of preclinical and clinical evidences on the possible efficacy of antidiabetic drugs in NAFLD treatment. Overall, available data suggest that metformin has beneficial effects on body weight reduction and metabolic parameters, with uncertain effects on liver histology, while pioglitazone may improve liver histology. Few data, mostly preclinical, are available on DPP4 inhibitors and GLP-1 analogues. The heterogeneity of these studies and the small number of patients do not allow for firm conclusions about treatment guidelines, and further randomized, controlled studies are needed.
Keywords: nonalcoholic fatty liver disease (NAFLD); insulin resistance; type 2 diabetes mellitus (T2DM); cardiovascular disease (CVD); antidiabetic drugs; statins nonalcoholic fatty liver disease (NAFLD); insulin resistance; type 2 diabetes mellitus (T2DM); cardiovascular disease (CVD); antidiabetic drugs; statins
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Fruci, B.; Giuliano, S.; Mazza, A.; Malaguarnera, R.; Belfiore, A. Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment. Int. J. Mol. Sci. 2013, 14, 22933-22966.

AMA Style

Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A. Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment. International Journal of Molecular Sciences. 2013; 14(11):22933-22966.

Chicago/Turabian Style

Fruci, Barbara; Giuliano, Stefania; Mazza, Angela; Malaguarnera, Roberta; Belfiore, Antonino. 2013. "Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment." Int. J. Mol. Sci. 14, no. 11: 22933-22966.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert